Medicenna Therapeutics Corp
Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, a long-acting interleuk… Read more
Market Cap & Net Worth: Medicenna Therapeutics Corp (MDNAF)
Medicenna Therapeutics Corp (OTCQX:MDNAF) has a market capitalization of $53.30 Million ($53.30 Million) as of March 19, 2026. Listed on the OTCQX stock exchange, this USA-based company holds position #22043 globally and #7838 in its home market, demonstrating a -9.36% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Medicenna Therapeutics Corp's stock price $0.64 by its total outstanding shares 83411435 (83.41 Million).
Medicenna Therapeutics Corp Market Cap History: 2017 to 2025
Medicenna Therapeutics Corp's market capitalization history from 2017 to 2025. Data shows change from $133.54 Million to $53.30 Million (-10.66% CAGR).
Medicenna Therapeutics Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Medicenna Therapeutics Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of MDNAF by Market Capitalization
Companies near Medicenna Therapeutics Corp in the global market cap rankings as of March 19, 2026.
Key companies related to Medicenna Therapeutics Corp by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Medicenna Therapeutics Corp Historical Marketcap From 2017 to 2025
Between 2017 and today, Medicenna Therapeutics Corp's market cap moved from $133.54 Million to $ 53.30 Million, with a yearly change of -10.66%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $53.30 Million | -49.29% |
| 2024 | $105.10 Million | +313.11% |
| 2023 | $25.44 Million | -33.41% |
| 2022 | $38.20 Million | -71.90% |
| 2021 | $135.96 Million | -65.17% |
| 2020 | $390.37 Million | +80.00% |
| 2019 | $216.87 Million | +401.74% |
| 2018 | $43.22 Million | -67.63% |
| 2017 | $133.54 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Medicenna Therapeutics Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $53.30 Million USD |
| MoneyControl | $53.30 Million USD |
| MarketWatch | $53.30 Million USD |
| marketcap.company | $53.30 Million USD |
| Reuters | $53.30 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.